Boston Scien Cp SEC Filings

Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported option activity and open-market sales on 10/01/2025. The filing shows a grant of a stock option to purchase 50,000 shares with an exercise price of $26.15; the option vests in four equal annual installments and the reported exercisable/expiration schedule lists an expiration of 12/01/2027. On the same date the reporting person sold 8,245 shares at a weighted average price of $98.9063 and 41,755 shares at a weighted average price of $98.3797, totaling 50,000 shares sold. The transactions were effected under a pre-established Rule 10b5-1 trading plan adopted 02/27/2025. The report disclaims beneficial ownership of 5,234 shares held by the reporting person’s child. The Form 4 was signed by an attorney-in-fact on 10/01/2025.

Insider sale notice for Boston Scientific (BSX): This Form 144 reports a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC on 10/01/2025 with an aggregate market value of $4,923,325 and 1,481,751,634 shares outstanding. The securities were acquired and are to be sold following a stock option exercise on 10/01/2025 with cash payment. The filer (identified in past sales as Joseph M. Fitzgerald) previously sold 50,000 shares on 09/02/2025 for $5,271,415 and 50,000 shares on 08/01/2025 for $5,231,665. The filer certifies no undisclosed material information and includes standard Rule 144 representations.

Boston Scientific Corporation announced that Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, will retire effective December 1, 2025 and remain as a senior advisor through February 27, 2026. During the advisory period he will receive his current base salary of $705,000, prorated to the Retirement Date. The company expects to enter a Retirement Agreement providing payments and benefits materially consistent with its Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and related equity awards.

Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported multiple transactions on 09/02/2025 effected under a pre-established Rule 10b5-1 trading plan adopted February 27, 2025. The report shows 50,000 shares acquired at a price of $26.15 (code M) and two dispositions totaling 50,000 shares sold in multiple trades at weighted average prices of $104.886 and $105.8486. After these transactions, the reporting person beneficially owned 178,342 shares directly, with an additional 5,234 shares held indirectly by his child which he disclaims beneficial ownership of. The filing includes an option related entry reflecting a 50,000-share option with the same $26.15 figure and references vesting in four equal annual installments beginning December 1, 2018.

The form is signed by an attorney-in-fact on behalf of the reporting person and discloses the reporting person will provide detailed per-price sale breakdowns upon request by the SEC or others.

Boston Scientific Corp. Form 144 notice reports a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $5,271,415.00, with an approximate sale date of 09/02/2025. The filing states these 50,000 shares were acquired the same day by stock option exercise and paid for in cash.

The filing also discloses prior sales by the same person, JOSEPH M FITZGERALD, totaling 156,372 shares across three transactions on 06/04/2025, 07/01/2025, and 08/01/2025, generating gross proceeds of $16,985,599.64 combined. The notice includes the seller's representation that no undisclosed material adverse information is known.